Celgene Corporation (CELG) Shares Sold by Sumitomo Mitsui Asset Management Company LTD
Sumitomo Mitsui Asset Management Company LTD decreased its position in Celgene Corporation (NASDAQ:CELG) by 7.0% during the first quarter, according to its most recent disclosure with the SEC. The fund owned 137,913 shares of the biopharmaceutical company’s stock after selling 10,459 shares during the period. Sumitomo Mitsui Asset Management Company LTD’s holdings in Celgene Corporation were worth $17,160,000 at the end of the most recent reporting period.
Several other large investors also recently made changes to their positions in CELG. Headinvest LLC acquired a new position in Celgene Corporation during the fourth quarter worth about $2,667,000. Edge Wealth Management LLC boosted its position in Celgene Corporation by 10.5% in the first quarter. Edge Wealth Management LLC now owns 15,920 shares of the biopharmaceutical company’s stock valued at $1,979,000 after buying an additional 1,518 shares in the last quarter. Russell Investments Group Ltd. purchased a new position in Celgene Corporation during the fourth quarter valued at $55,336,000. Essex Financial Services Inc. boosted its position in Celgene Corporation by 5.8% in the fourth quarter. Essex Financial Services Inc. now owns 28,072 shares of the biopharmaceutical company’s stock valued at $3,249,000 after buying an additional 1,543 shares in the last quarter. Finally, Catawba Capital Management VA boosted its position in Celgene Corporation by 12.0% in the first quarter. Catawba Capital Management VA now owns 2,425 shares of the biopharmaceutical company’s stock valued at $302,000 after buying an additional 260 shares in the last quarter. 78.26% of the stock is owned by institutional investors and hedge funds.
Celgene Corporation (NASDAQ:CELG) traded up 1.36% during mid-day trading on Monday, reaching $124.02. 1,315,724 shares of the company’s stock traded hands. The firm’s 50-day moving average price is $119.11 and its 200 day moving average price is $119.63. The firm has a market cap of $96.84 billion, a price-to-earnings ratio of 46.57 and a beta of 1.82. Celgene Corporation has a one year low of $94.42 and a one year high of $127.64. Celgene Corporation also was the target of unusually large options trading activity on Friday. Stock investors bought 1,785 call options on the company. This is an increase of 104% compared to the typical volume of 873 call options.
Celgene Corporation (NASDAQ:CELG) last released its quarterly earnings results on Thursday, April 27th. The biopharmaceutical company reported $1.68 EPS for the quarter, topping analysts’ consensus estimates of $1.47 by $0.21. Celgene Corporation had a net margin of 18.32% and a return on equity of 70.94%. The firm had revenue of $2.96 billion during the quarter, compared to analysts’ expectations of $3.04 billion. During the same period in the previous year, the company earned $1.32 EPS. The firm’s revenue for the quarter was up 17.8% compared to the same quarter last year. On average, equities analysts forecast that Celgene Corporation will post $7.29 EPS for the current year.
CELG has been the topic of several research analyst reports. Zacks Investment Research lowered Celgene Corporation from a “buy” rating to a “hold” rating in a research note on Thursday, March 9th. Mizuho set a $130.00 target price on Celgene Corporation and gave the company a “buy” rating in a research report on Sunday, February 19th. BTIG Research reissued a “buy” rating and set a $138.00 price target on shares of Celgene Corporation in a research report on Wednesday, May 24th. Cann reissued an “outperform” rating and set a $148.00 price target on shares of Celgene Corporation in a research report on Friday, February 24th. Finally, Leerink Swann reissued a “market perform” rating on shares of Celgene Corporation in a research report on Monday, March 20th. Two analysts have rated the stock with a sell rating, five have assigned a hold rating, twenty have issued a buy rating and one has assigned a strong buy rating to the stock. Celgene Corporation presently has an average rating of “Buy” and a consensus price target of $139.49.
In other news, insider Rupert Vessey sold 4,785 shares of the business’s stock in a transaction dated Thursday, June 15th. The shares were sold at an average price of $120.18, for a total value of $575,061.30. Following the completion of the sale, the insider now owns 4,004 shares in the company, valued at approximately $481,200.72. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director James J. Loughlin sold 9,250 shares of the business’s stock in a transaction dated Monday, May 1st. The shares were sold at an average price of $124.00, for a total transaction of $1,147,000.00. Following the completion of the sale, the director now owns 32,169 shares of the company’s stock, valued at approximately $3,988,956. The disclosure for this sale can be found here. Insiders have sold a total of 28,068 shares of company stock valued at $3,459,768 in the last quarter. 0.95% of the stock is currently owned by company insiders.
About Celgene Corporation
Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.
Receive News & Stock Ratings for Celgene Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene Corporation and related stocks with our FREE daily email newsletter.